Conference co-chair Elaine R. Mardis, PhD, discusses the third conference in the AACR's Precision Medicine Series, “Integrating Clinical Genomics...
This year, at the AACR Annual Meeting held in Philadelphia April 18 to 22, an astounding 19,300 members of...
In my first post in this series highlighting some of the studies presented at the AACR Annual Meeting 2015...
Game-changing modern cancer therapies—immunotherapies and targeted therapies, among others—have been providing promising treatment outcomes in the recent years. The...
There has been a series of immunotherapy approvals since the end of last year, and following this trend, on...
On Jan. 30, President Obama proposed a $215 million Precision Medicine Initiative, with the goal of revolutionizing medicine. This...
When the hottest minds in cancer genomics meet the hottest minds in computational and systems biology, you can rest...
Big progress was made in 2014, in the form of FDA approvals for new immunotherapies, targeted therapies, and a...
Adding the PI3-kinase inhibitor pictilisib to fulvestrant doubled progression-free survival for some women with advanced hormone-receptor positive breast cancer,...
After making great strides for some patients with melanoma and lung cancer, immunotherapy drugs are starting to offer hope...